BioOutsource plans Global Expansion
BioOutsource Ltd. announced that the last 12 months have been an exceptional growth year for the company. Global demand for outsourced testing services, coupled with BioOutsource’s continued investment in R&D and the opening of a state of the art BioSimilar Centre of Excellence in Glasgow in February 2014, has driven continued development of the company and created the need to establish a new North American Testing Facility in 2015.

Left to Right: MassBio President & CEO Robert Coughlin, Massachusetts Senate President Therese Murray, BioOutsource CEO Gerry McKay, Governor Deval Patrick, and Massachusetts Life Sciences Center President & CEO Susan Windham-Bannister, Ph.D. celebrate BioOutsource’s decision to expand in Massachusetts at the BIO Convention in San Diego.
BioOutsource revenues have grown by more than 40% over the last 12 months with positive growth delivered across all business units. The company continues to strengthen and reinforce its position as market leader in the biological analysis of BioSimilar molecules.
Following the successful opening of a US office in 2013, based in the BioTechnology Hub of Cambridge, MA, the company plans to open a Laboratory Facility in the Massachusetts area in early 2015 to service their North American & Latin American clients. The new Laboratory Facility will support and strengthen the company’s BioSimilar and BioSafety service offering.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Marijuana compound may offer treatment for Alzheimer's disease - New preclinical study indicates THC may slow or halt progression of memory-robbing disease
Epigenomics Biomarker Predicts Drug Resistance in Colorectal Cancer
Gerresheimer modernizing its Pfreimd site - Company switching to a more powerful, more energy-efficient technology
Medtech company Theraclion obtains €8.5 million in R&D funding from OSEO
Alternative methods replace animal experiments: 20 years successful work by ZEBET within BfR - ZEBET celebrates its anniversary with an international symposium at BfR in Berlin
OPK Biotech Develops Research and Production in Russia

ImClone Systems Incorporated - New York City, USA

C2N Diagnostics - St. Louis, USA
